VRTX SEC Filing News — Vertex Pharmaceuticals Incorporated

Q: What is the difference between a 10-K and 10-Q for VRTX?

The 10-K is Vertex Pharmaceuticals Incorporated's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Latest SEC filings for Vertex Pharmaceuticals Incorporated (VRTX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-10.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for peo…

Sector: Healthcare Industry: Biotechnology Market Cap: $128.8B CIK: 875320

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for VRTX currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

VRTX Filing Activity Snapshot 2026-06-26 — 2026-09-10

Insider Transactions (Form 4)

0 buys vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$799.8K

McKechnie Duncan (EVP, Chief Commercial Officer) · 2026-07-07

1,541 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Vertex Pharmaceuticals Incorporated.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 6 compensation award, 4 open-market sale and 1 gift. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Gift ×1: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Form 4 Compensation award Tax / Compensation Filing 2026-09-10

VRTX insider Form 4 filed for equity award, exercise, or tax withholding

van Grunsven Jasper (EVP, CP and NPPO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	8,682	—	—

Filing: Form 4 (Insider Transaction) Insider: van Grunsven Jasper (EVP, CP and NPPO) Shares: 8,682

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-01

VRTX insider Form 4 filed for equity award, exercise, or tax withholding

Ambrose Kristen (SVP & Chief Accounting Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	5,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Ambrose Kristen (SVP & Chief Accounting Officer) Shares: 5,000

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-08-31

VRTX insider Form 4 filed for equity award, exercise, or tax withholding

SACHS BRUCE I (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	6,000	—	—

Filing: Form 4 (Insider Transaction) Insider: SACHS BRUCE I (Director) Shares: 6,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-23

VRTX insider Form 4 filed for equity award, exercise, or tax withholding

Tatsis Ourania (EVP, Chief Reg. & Quality Off.) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	8,251	—	—

Filing: Form 4 (Insider Transaction) Insider: Tatsis Ourania (EVP, Chief Reg. & Quality Off.) Shares: 8,251

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-23

VRTX insider Form 4 filed for equity award, exercise, or tax withholding

Sachdev Amit (EVP Chief Patient & Ext Af Off) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	8,251	—	—

Filing: Form 4 (Insider Transaction) Insider: Sachdev Amit (EVP Chief Patient & Ext Af Off) Shares: 8,251

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

VRTX insider Form 4 filed for equity award, exercise, or tax withholding

SACHS BRUCE I (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Deferred Stock Units	99	$475.28	$47.1K

Filing: Form 4 (Insider Transaction) Insider: SACHS BRUCE I (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

VRTX insider Form 4 filed for equity award, exercise, or tax withholding

Garber Alan M (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Deferred Stock Units	31	$475.28	$14.7K

Filing: Form 4 (Insider Transaction) Insider: Garber Alan M (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-07

VRTX insider Tatsis Ourania (EVP, Chief Reg. & Quality Off.) sold 1,500 shares (~$787.5K)

Tatsis Ourania, listed as EVP, Chief Reg. & Quality Off. at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 1,500 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,500	$524.99	$787.5K

Filing: Form 4 (Insider Transaction) Insider: Tatsis Ourania (EVP, Chief Reg. & Quality Off.) Shares: 1,500 Est. Value: $787.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-07

VRTX insider McKechnie Duncan (EVP, Chief Commercial Officer) sold 1,541 shares (~$799.8K)

McKechnie Duncan, listed as EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 1,541 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,541	$519.00	$799.8K

Filing: Form 4 (Insider Transaction) Insider: McKechnie Duncan (EVP, Chief Commercial Officer) Shares: 1,541 Est. Value: $799.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-06

VRTX insider Liu Joy (EVP and Chief Legal Officer) sold 828 shares (~$416.2K)

Liu Joy, listed as EVP and Chief Legal Officer at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 828 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	828	$502.71	$416.2K

Filing: Form 4 (Insider Transaction) Insider: Liu Joy (EVP and Chief Legal Officer) Shares: 828 Est. Value: $416.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-30

VRTX insider Bozic Carmen (EVP and CMO) sold 596 shares (~$287.6K)

Bozic Carmen, listed as EVP and CMO at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 596 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	596	$482.50	$287.6K

Filing: Form 4 (Insider Transaction) Insider: Bozic Carmen (EVP and CMO) Shares: 596 Est. Value: $287.6K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Vertex Pharmaceuticals Incorporated has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-27

VRTX Form 144 filed for proposed insider sale by Bruce I. Sachs (1,210 shares) ~$662.5K

Bruce I. Sachs filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Bruce I. Sachs Shares: 1,210 Est. Value: $662.5K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-02

VRTX Form 144 filed for proposed insider sale by Tatsis Ourania (1,500 shares) ~$787.5K

Tatsis Ourania filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Tatsis Ourania Shares: 1,500 Est. Value: $787.5K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-02

VRTX Form 144 filed for proposed insider sale by McKechnie Duncan (1,541 shares) ~$799.8K

McKechnie Duncan filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: McKechnie Duncan Shares: 1,541 Est. Value: $799.8K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-01

VRTX Form 144 filed for proposed insider sale by Liu Joy (828 shares) ~$416.2K

Liu Joy filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Liu Joy Shares: 828 Est. Value: $416.2K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-26

VRTX Form 144 filed for proposed insider sale by Bozic Carmen (596 shares) ~$287.6K

Bozic Carmen filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Bozic Carmen Shares: 596 Est. Value: $287.6K

View on SEC EDGAR → Open Filing Document →

Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Vertex Pharmaceuticals Incorporated. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-01

VRTX filed 8-K — material company event

VERTEX PHARMACEUTICALS INC / MA filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-03

VRTX filed 8-K — material company event

VERTEX PHARMACEUTICALS INC / MA filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-07

VRTX filed 8-K — material company event

VERTEX PHARMACEUTICALS INC / MA filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Vertex Pharmaceuticals Incorporated.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-04

VRTX filed Quarterly Report (10-Q)

VERTEX PHARMACEUTICALS INC / MA filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Vertex Pharmaceuticals Incorporated's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on VRTX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — VRTX SEC Filings

What SEC filings does Vertex Pharmaceuticals Incorporated submit to the SEC?

Vertex Pharmaceuticals Incorporated (VRTX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about VRTX?

A Form 4 for VRTX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Vertex Pharmaceuticals Incorporated?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for VRTX?

The 10-K is Vertex Pharmaceuticals Incorporated's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all VRTX SEC filings directly on EDGAR?

You can view all historical Vertex Pharmaceuticals Incorporated filings on the SEC EDGAR company page for VRTX. Each filing card on this page links directly to the original SEC document.

How often does Vertex Pharmaceuticals Incorporated file with the SEC?

Vertex Pharmaceuticals Incorporated files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling VRTX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

More Tools for VRTX

VRTX Full Stock Analysis VRTX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper VRTX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the VRTX stock analysis page.

VRTX Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer